Latest Conference Coverage

Ponesimod Linked to Low Levels of Disease Activity in Relapsing Multiple Sclerosis

No new safety signals were observed in the combined analysis of ponesimod from the phase 2b core study and extension study.

COVID-19 Has Negative Impact on Parkinson Disease Symptom Management

Supporting patient activation of their knowledge, skill, and confidence in managing their health may empower patients in times of stress.

Parkinson Disease Gene Therapy VY-AADC01 Proves Safe With Signs of Efficacy

Three-year data from a phase 1 study of Voyager Therapeutics’ VY-AADC01 suggest it is safe and offers potential benefits for patients with Parkinson disease.

Bilateral Focused Ultrasound Thalamotomy Safe, Effective in Essential Tremor

Scores reflective of tremor in each body part and task performance improved by 71% in patients from baseline before first thalamotomy to 6 months after second thalamotomy.

Directional Deep Brain Stimulation Linked to Wider Therapeutic Window in Parkinson Disease

After 3 months of treatment, an overwhelming number of clinicians and patients preferred directional over omnidirectional DBS.

Cannabinoid May Improve Nonmotor Symptoms in Parkinson Disease

Results from a phase 2 pilot study of nabilone in Parkinson disease suggest that the synthetic cannabinoid might hold therapeutic potential for nonmotor symptoms.

Ofatumumab Highly Effective in Treatment-Naïve Relapsing-Remitting Multiple Sclerosis

Treatment-naïve patients showed consistent results with the overall study population that was observed in the ASCLEPIOS I and II trials.

Disability, Economic Burden Greater in MS Patients With High Levels of Fatigue

Patients with relapsing multiple sclerosis and high levels of fatigue were less likely to be employed full-time than those with MS with low fatigue.

Pitolisant Shows No Cardiac Safety Signals in Narcolepsy

Despite previous literature documenting cardiovascular disease comorbidity in patients with narcolepsy, pitolisant treatment did not demonstrate any cardiac safety signals.

Solriamfetol Improves Excessive Daytime Sleepiness and Driving Performance Ability

The FDA-approved agent showed significant impact in decreasing standard deviation of lateral position, a measure used to assess driving performance.

Pitolisant Improves Daytime Sleepiness and Cataplexy in Severely Burdened Patients

Pooled data from 2 clinical trials of the H3-receptor antagonist/inverse agonist show it improved cataplexy and excessive daytime sleepiness in patients with narcolepsy who were most hampered by symptoms.

Marwan Sabbagh, MD: Observations From AAIC 2020

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic detailed the state of Alzheimer disease and what research particularly grabbed his attention at AAIC 2020.

Lemborexant Demonstrates Efficacy in Elders

Already FDA approved for the treatment of insomnia in adults, lemborexant’s ability to improve sleep outcomes in the elderly was highlighted in a study presented at SLEEP 2020.

Lemborexant Improves Sleep Outcomes Following Placebo Randomization Switch

Benefit from lemborexant was evident after 1 month of switching from placebo to the active treatment and was sustained through the entirety of the 12-month trial.

Cognitive Behavioral Therapy for Insomnia Shows Multiple Benefits for Women

Multiple abstracts at SLEEP 2020 show CBT-I’s success in aiding women with insomnia, including those going through pregnancy, and those who are veterans both with and without PTSD.

Katrina Celis, MD: Genetics and Their Role in Alzheimer Research, Clinical Care

The postdoctoral fellow at the University of Miami Miller School of Medicine detailed the role that increased APOE ε4 expression can have on future research and clinical care.

Q&A: Genetic Ancestry and Alzheimer Disease Risk

Katrina Celis, MD, a postdoctoral fellow at the University of Miami Miller School of Medicine, discussed how ancestral genetics can play a key role in Alzheimer disease risk.

Sargramostim Shows Safety and Promise as Potential Alzheimer Treatment

The investigators wrote that the Alzheimer’s Association “Part the Cloud” funded 24-week treatment trial is now warranted after sargramostim showed a safe and tolerable profile.

Dementia-Related Psychosis Places Heavy Burden on Patients and Caretakers

Data from 2 posters presented at AAIC 2020 suggest that there is an unmet need for safe and effective treatments for patients who experience dementia-related psychosis.

Raymond S. Turner, MD, PhD: Safety Results for Nilotinib in Alzheimer

The director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center detailed the phase 2 study findings of nilotinib in patients with Alzheimer disease.

12 Modifiable Risk Factors to Reduce Dementia Risk

Excessive alcohol intake, head injury, and air pollution are among the newest dementia risk factors added to the Lancet Commission report.

Nilotinib Safety Profile Sets Agent Up For Phase 3 Study

The director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center details his findings from the phase 2 study of nilotinib in patients with Alzheimer disease.

Katrina Celis, MD: Ancestral Genetics and the Impact on Alzheimer Disease Risk

The postdoctoral fellow at the University of Miami Miller School of Medicine detailed her study presented at AAIC 2020 that examined Alzheimer risk associated with APOE ε4 in different genetic populations.

Hypertension, Diabetes, High BMI All Early Life Risk Factors for Dementia

Multiple studies presented at AAIC 2020 highlight and confirm previous hypotheses of the role that early life cardiovascular risk factors play for individuals who develop late life dementia.

VU319 Shows Safe Profile and Potential as M1 Allosteric Modulator for MCI

The data suggests that a planned multiple ascending dose study and a phase 2a proof-of-concept study in patients with mild cognitive impairment could be on the way.

Nilotinib Has Safe and Tolerable Profile in Alzheimer Disease

Results presented virtually at AAIC 2020 support a larger, multi-center, phase 3 study to determine the safety and efficacy of nilotinib in patients with Alzheimer disease.

Candesartan Shows Signs of Neuroprotection in Older Adults With MCI and Hypertension

Compared to treatment with lisinopril, those treated with the angiotensin receptor blocker candesartan showed improvements on the Trial Making Test part A and B and Hopkins Verbal Learning Test-Revised delayed recall.

Pimavanserin Reduces Dementia-Related Psychosis Symptoms

Additional data presented at AAIC 2020 shows the clinical benefit pimavanserin has on dementia-related psychosis while the agent awaits a PDUFA date of April 3, 2021.

P-Tau217 May Detect Alzheimer Disease, Brain Amyloidosis, Tauopathy

The performance of p-tau217 was similar to significantly more costly methods, such as PET imaging and measuring cerebrospinal fluid biomarkers.

Influenza, Pneumonia Vaccination May Reduce Alzheimer Disease Risk

A trio of studies presented at AAIC 2020 suggest that consistently vaccinations for influenza and pneumonia may reduce the incidence of Alzheimer later in life, as well as mortality for older adults.